Our results suggest that periostin is down-regulated in AS patients with highly active disease and may contribute to disease pathogenesis through an interaction with Wnt signaling.

BackgroundAnkylosing spondylitis (AS) is a chronic rheumatic disease characterized by sacroiliac and spinal inflammation and new bone formation (syndesmophyte). Molecular mechanisms underlying this process have not been yet fully understood however differentiation of mesenchymal cells into bone-forming osteoblasts appears to be a key pathogenic event. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor and have some pro-inflammatory activity. It has also been suggested that VEGF may be relevant for new bone formation in AS.ObjectivesTo evaluate the serum VEGF and osteocalcin levels in patients with AS. We also assessed the relationship among VEGF/osteocalcin levels and disease related parameters including radiographic outcomes.MethodsIn total 98 consecutive AS patients (77 males [79%]; with a mean age of 39.3±10.0 years) according to the modified New York criteria and 49 healthy controls (37males [76%]; with a mean age of 39.0±5.9 years) from two centers were included in the study. Serum VEGF, osteocalcin, interleukin (IL)-8, IL-6 levels were measured by commercially available ELISA kits. We also determined the serum high-sensitivity C-reactive protein (hs-CRP) levels. Disease related characteristics of patients were assessed by using BASDAI, BASFI, BASMI. Radiographs of the pelvis, cervical and lumbar spine were scored by using the modified New York and modified Stokes ankylosing spondylitis spinal score (mSASSS).ResultsAge and sex distribution were not different between AS patients and control subjects. As expected hs-CRP levels and erythrocyte sedimentation rate were higher in AS patients in comparison with controls. Serum VEGF level was found to be significantly higher in our AS patients compared with controls. In our study group serum VEGF levels were correlated with hs-CRP (rho=0.285 and P=0.005), ESR (rho=0.247 and P=0.015), IL-6 level (rho=0.380 and P<0.001), IL-8 (rho=0.400 and P<0.001) and ASDAS-CRP (rho=0.203 and P=0.048). Serum VEGF level was found to be not associated with hip involvement, sacroiliac joint ankylosis or presence of the syndesmophyte. Our study showed that although serum osteocalcin level was not statistically different in AS patients and controls it was significantly higher in patients with sacroiliac joint ankylosis and hip involvement.Table 1AS patients (n=98)Controls (n=49)PAge at disease onset27.7±8.6N/AN/AMean BASDAI4.2±2.1N/AN/AMean BASFI3.4±2.4N/AN/AMean BASMI3.8±1.7N/AN/AASDAS-CRP3.0±0.9N/AN/AMedian mSASSS score6 (0-72)N/AN/ASerum VEGF (pg/mL)1591.71±753.55995.70±611.23<0.001Osteocalcin (mg/dL)5.8±7.36.3±8.40.0507IL-6 (pg/mL)22.3±161.66.6±31.2<0.001IL-8 (pg/mL)103.9±270.966.9±60.10.390hsCRP (μg/mL)5.2±8.40.7±1.3<0.001ESR25.6±22.510.8±9.2<0.001ConclusionsThe results of the present study showed that VEGF may be a good indicator of disease activity in AS and osteocalcin may have a role in new bone formation.Disclosure of InterestNone declared

No abstract

Amaç: Kliniğimizde solid organ transplantasyonu sonrası post-transplant lenfoproliferatif hastalık tanısı almış hastaların klinik bulgularını, laboratuar özelliklerini, genel ve progesyonsuz sağ kalımlarını değerlendirmeyi amaçladık. Yöntemler: Ocak 2000-Aralık 2018 yılları arasında solid organ transplantasynu sonrası post-transplant lenfoproliferatif hastalık tanısı alan hastalar retrospektif olarak incelendi. Hastaların cinsiyeti, transplantasyon oldukları yaş, lenfoproliferatif hastalık tanı yaşı, transplantasyon sonrası lenfoproliferatif hastalık tanısına kadar geçen süre, lenfoproliferatif hastalık için klinik prezentasyonları, tümör karakteristikleri, tanı anındaki laktat dehidrogenaz düzeyleri, immunsupresif tedavileri, lenfoproliferatif hastalık için aldıkları tedaviler ve bu tedavilere yanıtları, toplam ve olaysız sağ kalım değerlendirildi.

| 2019;3:S1 980 (16.9%), pallor (7.9%), neurological symptoms (5.6%) and finally oliguria (2.2%). CyBorD have better overall response rate (≥PR) (p = 0.031), PFS (p = 0.004) and DFS (p = 0.013) as 1st line treatment compared to VAD regimen. Also in previously treated patients CyBorD showed better PFS (p = 0.039) compared to VAD regimen. There was a significant relation between age (p = 0.001&<0.001) and ASCT (p = 0.001&0.034) with PFS and OS respectively.